Literature DB >> 24284467

Phosphodiesterase inhibition facilitates cognitive restoration in rodent models of age-related memory decline.

Bryan D Devan1, Paul J Pistell1, Kara B Duffy2, Bennett Kelley-Bell3, Edward L Spangler2, Donald K Ingram2.   

Abstract

BACKGROUND: Previous studies have shown that cyclic nucleotide phosphodiesterase type 5 (PDE5) inhibition with the drugs sildenafil and vardenafil can enhance spatial performance and object recognition in rodent models of learning and memory.
OBJECTIVE: We review recent studies on PDE5 inhibition and report novel data that specifically tests the systemic effects of both pharmacological agents in aged rats using two different spatial learning/memory paradigms.
METHODS: The 14-unit T-maze was used as a test of egocentric spatial processing that requires rats to learn a series of left/right turns to avoid mild footshock. The Morris water maze is a test of allocentric spatial learning that requires the acquisition of place information to localize a hidden platform relative to distal room cues.
RESULTS: In both cases, acquisition (i.e., learning performance) was not improved, however after a one week drug washout period, aged animals demonstrated improved spatial memory retention compared to aged controls, ruling out simple performance effects.
CONCLUSIONS: These findings are discussed in relation to recent reports on the use of PDE inhibitors to treat Alzheimer's disease (AD) dementia and age-related memory impairments. While some report promising pre-clinical results, others note that PDE5 may not be an appropriate target in AD due to a lack of localization within critical brain structures where therapeutic activity is needed. Despite these limitations, PDE5 inhibition may produce beneficial effects via several mechanisms that target predisposing risk factors leading to increased incidence of memory impairment in aged individuals and influence memory consolidation mechanisms that preserve long-term retention of cognitive information.

Entities:  

Keywords:  Alzheimer's disease; animal models; cognitive enhancement; phosphodiesterase inhibition

Mesh:

Substances:

Year:  2014        PMID: 24284467     DOI: 10.3233/NRE-131022

Source DB:  PubMed          Journal:  NeuroRehabilitation        ISSN: 1053-8135            Impact factor:   2.138


  10 in total

1.  HSPA5/Dna K may be a useful target for human disease therapies.

Authors:  Laurence Booth; Jane L Roberts; Paul Dent
Journal:  DNA Cell Biol       Date:  2015-03       Impact factor: 3.311

Review 2.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

3.  GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease.

Authors:  Laurence Booth; Jane L Roberts; Devin R Cash; Seyedmehrad Tavallai; Sophonie Jean; Abigail Fidanza; Tanya Cruz-Luna; Paul Siembiba; Kelly A Cycon; Cynthia N Cornelissen; Paul Dent
Journal:  J Cell Physiol       Date:  2015-07       Impact factor: 6.384

4.  Conserved age-related increases in hippocampal PDE11A4 cause unexpected proteinopathies and cognitive decline of social associative memories.

Authors:  Katy Pilarzyk; Latarsha Porcher; William R Capell; Steven D Burbano; Jeff Davis; Janet L Fisher; Nicole Gorny; Siena Petrolle; Michy P Kelly
Journal:  Aging Cell       Date:  2022-09-08       Impact factor: 11.005

Review 5.  Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.

Authors:  Elisa Zuccarello; Erica Acquarone; Elisa Calcagno; Elentina K Argyrousi; Shi-Xian Deng; Donald W Landry; Ottavio Arancio; Jole Fiorito
Journal:  Biochem Pharmacol       Date:  2020-01-21       Impact factor: 5.858

6.  PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease.

Authors:  Andrew F Teich; Mikako Sakurai; Mitesh Patel; Cameron Holman; Faisal Saeed; Jole Fiorito; Ottavio Arancio
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

7.  GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.

Authors:  Jane L Roberts; Mehrad Tavallai; Aida Nourbakhsh; Abigail Fidanza; Tanya Cruz-Luna; Elizabeth Smith; Paul Siembida; Pascale Plamondon; Kelly A Cycon; Christopher D Doern; Laurence Booth; Paul Dent
Journal:  J Cell Physiol       Date:  2015-10       Impact factor: 6.384

Review 8.  Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.

Authors:  Eric P Knott; Mazen Assi; Sudheendra N R Rao; Mousumi Ghosh; Damien D Pearse
Journal:  Int J Mol Sci       Date:  2017-03-24       Impact factor: 5.923

Review 9.  Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.

Authors:  Owen Sanders; Lekshmy Rajagopal
Journal:  J Alzheimers Dis Rep       Date:  2020-06-16

10.  AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded Proteins.

Authors:  Laurence Booth; Jane L Roberts; Heath Ecroyd; St Patrick Reid; Stefan Proniuk; Alexander Zukiwski; Abraham Jacob; Elsa Damonte; María J Tuñón; Paul Dent
Journal:  J Clin Cell Immunol       Date:  2016-09-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.